terfenadine	sertraline	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	36437	42330	D020280
terfenadine	sertraline	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	36437	42330	D020280
terfenadine	sertraline	1	2	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	36437	42330	D020280
terfenadine	sertraline	1	2	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	36437	42330	D020280
terfenadine	sertraline	1	3	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	36437	42330	D020280
terfenadine	sertraline	1	3	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	36437	42330	D020280
terfenadine	sertraline	2	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	36437	42330	D020280
terfenadine	sertraline	2	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	36437	42330	D020280
terfenadine	sertraline	2	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	36437	42330	D020280
terfenadine	sertraline	2	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	36437	42330	D020280
terfenadine	sertraline	2	3	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	36437	42330	D020280
terfenadine	sertraline	2	3	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	36437	42330	D020280
terfenadine	sertraline	2	4	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		42330	36437	42330	D020280
terfenadine	sertraline	2	4	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		42330	36437	42330	D020280
terfenadine	carbamazepine	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	2002	42330	2002
terfenadine	carbamazepine	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	2002	42330	2002
terfenadine	carbamazepine	1	2	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	2002	42330	2002
terfenadine	carbamazepine	1	2	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	2002	42330	2002
terfenadine	carbamazepine	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	2002	42330	2002
terfenadine	carbamazepine	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	2002	42330	2002
terfenadine	carbamazepine	2	2	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	2002	42330	2002
terfenadine	carbamazepine	2	2	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	2002	42330	2002
terfenadine	cisapride	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	35255	42330	D020117
terfenadine	cisapride	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	35255	42330	D020117
terfenadine	cisapride	1	2	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	35255	42330	D020117
terfenadine	cisapride	1	2	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	35255	42330	D020117
terfenadine	cisapride	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	35255	42330	D020117
terfenadine	cisapride	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	35255	42330	D020117
terfenadine	cisapride	2	2	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	35255	42330	D020117
terfenadine	cisapride	2	2	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	35255	42330	D020117
terfenadine	cisapride	2	4	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		42330	35255	42330	D020117
terfenadine	cisapride	2	4	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		42330	35255	42330	D020117
terfenadine	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	none	42330	none
terfenadine	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		42330	none	42330	none
terfenadine	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	none	42330	none
terfenadine	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	none	42330	none
terfenadine	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	none	42330	none
terfenadine	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		42330	none	42330	none
terfenadine	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	none	42330	none
terfenadine	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		42330	none	42330	none
sertraline	carbamazepine	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		36437	2002	D020280	2002
sertraline	carbamazepine	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		36437	2002	D020280	2002
sertraline	carbamazepine	1	2	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	2002	D020280	2002
sertraline	carbamazepine	1	2	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	2002	D020280	2002
sertraline	carbamazepine	2	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	2002	D020280	2002
sertraline	carbamazepine	2	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	2002	D020280	2002
sertraline	carbamazepine	2	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	2002	D020280	2002
sertraline	carbamazepine	2	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	2002	D020280	2002
sertraline	carbamazepine	3	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	2002	D020280	2002
sertraline	carbamazepine	3	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	2002	D020280	2002
sertraline	carbamazepine	3	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	2002	D020280	2002
sertraline	carbamazepine	3	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	2002	D020280	2002
sertraline	carbamazepine	4	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	2002	D020280	2002
sertraline	carbamazepine	4	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	2002	D020280	2002
sertraline	cisapride	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		36437	35255	D020280	D020117
sertraline	cisapride	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		36437	35255	D020280	D020117
sertraline	cisapride	1	2	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	35255	D020280	D020117
sertraline	cisapride	1	2	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	35255	D020280	D020117
sertraline	cisapride	2	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	35255	D020280	D020117
sertraline	cisapride	2	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	35255	D020280	D020117
sertraline	cisapride	2	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	35255	D020280	D020117
sertraline	cisapride	2	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	35255	D020280	D020117
sertraline	cisapride	2	4	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	2	4	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	3	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	35255	D020280	D020117
sertraline	cisapride	3	1	true	negative	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	35255	D020280	D020117
sertraline	cisapride	3	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	35255	D020280	D020117
sertraline	cisapride	3	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	35255	D020280	D020117
sertraline	cisapride	3	4	true	positive	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	3	4	true	positive	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	4	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	4	2	true	negative	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	4	4	true	positive	Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	cisapride	4	4	true	positive	Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	35255	D020280	D020117
sertraline	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		36437	none	D020280	none
sertraline	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		36437	none	D020280	none
sertraline	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	none	D020280	none
sertraline	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		36437	none	D020280	none
sertraline	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	3	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	3	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	3	3	false	none	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	3	3	false	none	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		36437	none	D020280	none
sertraline	p450	4	3	false	none	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	none	D020280	none
sertraline	p450	4	3	false	none	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		36437	none	D020280	none
carbamazepine	cisapride	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		2002	35255	2002	D020117
carbamazepine	cisapride	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		2002	35255	2002	D020117
carbamazepine	cisapride	1	2	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	35255	2002	D020117
carbamazepine	cisapride	1	2	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	35255	2002	D020117
carbamazepine	cisapride	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	35255	2002	D020117
carbamazepine	cisapride	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	35255	2002	D020117
carbamazepine	cisapride	2	2	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	35255	2002	D020117
carbamazepine	cisapride	2	2	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	35255	2002	D020117
carbamazepine	cisapride	2	4	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		2002	35255	2002	D020117
carbamazepine	cisapride	2	4	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		2002	35255	2002	D020117
carbamazepine	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		2002	none	2002	none
carbamazepine	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		2002	none	2002	none
carbamazepine	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		2002	none	2002	none
carbamazepine	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		2002	none	2002	none
carbamazepine	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	none	2002	none
carbamazepine	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		2002	none	2002	none
carbamazepine	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		2002	none	2002	none
carbamazepine	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		2002	none	2002	none
cisapride	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		35255	none	D020117	none
cisapride	p450	1	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  		35255	none	D020117	none
cisapride	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		35255	none	D020117	none
cisapride	p450	1	3	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		35255	none	D020117	none
cisapride	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		35255	none	D020117	none
cisapride	p450	2	1	false	none	In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.  The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  		35255	none	D020117	none
cisapride	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		35255	none	D020117	none
cisapride	p450	2	3	false	none	The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.  These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  		35255	none	D020117	none
cisapride	p450	4	3	false	none	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		35255	none	D020117	none
cisapride	p450	4	3	false	none	These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.  Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).  		35255	none	D020117	none
